EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study

Álvaro Rodríguez-Lescure, Javier Gallego, Pilar Garcia-Alfonso, Bartomeu Massuti, Raúl Márquez, Lourdes Calvo, Pedro Sánchez-Rovira, Antonio Antón, José Ignacio Chacón, Eva Ciruelos, Jose Juan Ponce, Ana Santaballa und 12 weitere

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03411-w ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Álvaro Rodríguez-Lescure und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital General Universitario de Elche, Carrer Almazara, 11, 03203, Elche, Alicante, Spain. alescure@geicam.org. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Breast Neoplasms, Hypertension. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sociedad Española de Oncología Médica, Instituto de Salud Carlos III, Roche España.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.

Methods

This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment. Blood pressure (BP) levels were measured (conventional and 24-h Holter monitoring) at baseline and up to cycle 3. Primary endpoint assessed BP levels increase as predictive factor for progression-free survival (PFS). Germline DNA methylation profile was explored in pre-treatment blood samples; principal component analysis was used to define an epigenetic predictive score for increased BP levels.

Results

From Oct-2012 to Jul-2016, 143 (78 MBC and 65 mCRC) patients were included. The incidence of AHT according to guidelines was neither predictive of PFS nor of best overall tumor response (BOR). No statistically significant association was observed with systolic BP nor diastolic BP increment for PFS or BOR. Grade 3 and 4 adverse events were observed in 37 and 5% of patients, respectively. We identified 27 sites which baseline methylation status was significantly associated to BP levels increase secondary to bevacizumab-containing chemotherapy.

Conclusions

Neither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy. Clinical trial registry ClinicalTrials.gov Identifier: NCT01733628.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabColorectal NeoplasmsBreast NeoplasmsHypertensionHumansFemaleMiddle AgedProspective StudiesAgedMaleAdultAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overProgression-Free SurvivalDNA Methylation

Stichwörter der Autor:innen

BevacizumabBlood pressureMetastatic breast cancerMetastatic colorectal cancer

Substanzen

Bevacizumab

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital General Universitario de Elche, Carrer Almazara, 11, 03203, Elche, Alicante, Spain. alescure@geicam.org.
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain. alescure@geicam.org.
  • Medical Oncology Department, Hospital General Universitario de Elche, Carrer Almazara, 11, 03203, Elche, Alicante, Spain.
  • Instituto de Investigación Sanitaria Gregorio Marañón, Facultad de Medicina de la Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario Dr. Balmis, Alicante, Spain.
  • GEICAM Spanish Breast Cancer Group, Madrid, Spain.

Förderung

  • Sociedad Española de Oncología Médica
  • Instituto de Salud Carlos III
  • Roche España

Zitieren

APA

Rodríguez-Lescure, Á., Gallego, J., Garcia-Alfonso, P., Massuti, B., Márquez, R., Calvo, L., Sánchez-Rovira, P., Antón, A., Chacón, J. I., Ciruelos, E., Ponce, J. J., Santaballa, A., Valladares-Ayerbes, M., Dueñas, M. R., Alonso, V., Aparicio, J., Encinas, S., Robles, L., Escudero, M. J., …, & de la Haba-Rodriguez, J. (2024). Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03411-w

Vancouver

Rodríguez-Lescure Á, Gallego J, Garcia-Alfonso P, Massuti B, Márquez R, Calvo L, et al. Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03411-w

BibTeX
@article{RodrguezLescure2024,
  author = {Rodríguez-Lescure, Álvaro and Gallego, Javier and Garcia-Alfonso, Pilar and Massuti, Bartomeu and Márquez, Raúl and Calvo, Lourdes and Sánchez-Rovira, Pedro and Antón, Antonio and Chacón, José Ignacio and Ciruelos, Eva and Ponce, Jose Juan and Santaballa, Ana and Valladares-Ayerbes, Manuel and Dueñas, María Rosario and Alonso, Vicente and Aparicio, Jorge and Encinas, Sara and Robles, Luis and Escudero, María José and Caballero, Rosalía and Bezares, Susana and García-Ortiz, María Victoria and Morales-Ruiz, Teresa and de la Haba-Rodriguez, Juan},
  title = {Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03411-w}
}
Kostenlos starten →